Published in:
01-06-2016 | Original Article
Diagnostic value of metabolic heterogeneity as a reliable parameter for differentiating malignant parotid gland tumors
Published in: Annals of Nuclear Medicine | Issue 5/2016
Login to get accessAbstract
Objective
Exact classifying between malignant and benign tumors in the parotid gland is important because the cancer has relatively poor prognosis. There have been several studies that F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) can differentiate between malignant and benign parotid gland tumors. However, the role of FDG PET is still controversial because many benign parotid gland tumors, such as Warthin’s tumor and pleomorphic adenoma, show high FDG uptake. We hypothesized that metabolic heterogeneity would differentiate malignant parotid tumors because tumoral heterogeneity is an important characteristic in the malignancies.
Methods
From January 2010 to April 2015, we retrospectively reviewed the 46 patients who showed FDG uptake at the parotid gland. To differentiate malignant parotid gland tumors, we obtained maximum SUV and mean SUV. Metabolic
tumor volume and total lesion glycolysis were measured as metabolic volumetric parameters. We also included heterogeneity parameters of FDG PET such as heterogeneity factor (HF) and the coefficient of variation for all patients.
Results
There was significant difference of HF between malignant (−0.30 ± 0.25; range −0.937 to −0.084) and benign parotid gland tumors (−0.06 ± 0.05; range −0.291 to −0.012; p < 0.0001). In receiver operating characteristic analysis, when ≤−0.084 was used as the cut-off value for HF, the sensitivity and specificity were 100 % (95 % CI 81.5–100) and 89.2 % (95 % CI 71.8–97.7), respectively. HF showed the highest area under the curve of 0.947 among the parameters. In logistic regression analysis, the HF was the most powerful factor for differentiation of the parotid gland tumors (p = 0.002).
Conclusions
Our results suggest that HF can be utilized as a reliable and non-invasive method for differentiation of malignant and benign parotid gland tumors.